Purpose Malignant glioma (MG) is the most deadly primary brain cancer. Signaling though
the PI3K/AKT/mTOR axis is activated in most MGs and therefore a potential therapeutic …

BACKGROUND Mitogen‐activated protein kinase (MAPK) activation and mammalian target
of rapamycin (mTOR)‐dependent signaling are hallmarks of glioblastoma. In the current …

Background Temsirolimus (CCI-779) is a small-molecule inhibitor of the mammalian target
of rapamycin (mTOR) and represents a rational therapeutic target against glioblastoma …

2006 Background: The activity of targeted molecular therapy with single agents has been
disappointing in GBM. Combination therapy simultaneously targeting both the …

Background Laboratory and clinical data suggest that the anti-angiogenic agent,
thalidomide, if combined with cytotoxic agents, may be effective against recurrent …

Background Inhibition of epidermal growth factor receptor (EGFR) and the mechanistic
target of rapamycin (mTOR) may have synergistic antitumor effects in high-grade glioma …

Background: Bevacizumab combined with chemotherapy has recently shown promising
efficacy in recurrent high-grade glioma. Phosphatase and tensin homolog (PTEN) mutation …

2004 Background: Glioblastomas (GBM) frequently have EGFR amplification/mutations and
inactivation of PTEN. Although single agent EGFR and mTOR inhibitors have limited activity …

We undertook this phase I study to investigate the feasibility of the combination of
temozolomide (TMZ) and lapatinib (LP) and to define the maximum tolerated dose (MTD) of …

BACKGROUND: Purpose: The ras/raf signaling pathway is crucial in the development of
pediatric low-grade gliomas (LGGs). Aberrant ras/raf signaling is involved in tumorigenesis …